Scarica l'app Stockscreener
0.703
8.47%
0.0549
Dopo l'orario di chiusura:
.74
0.037
+5.26%
Precedente Chiudi:
$0.6481
Aprire:
$0.65
Volume 24 ore:
434.69K
Relative Volume:
1.53
Capitalizzazione di mercato:
$62.06M
Reddito:
-
Utile/perdita netta:
$-23.64M
Rapporto P/E:
-2.2817
EPS:
-0.3081
Flusso di cassa netto:
$-12.89M
1 W Prestazione:
+29.94%
1M Prestazione:
-34.91%
6M Prestazione:
-62.61%
1 anno Prestazione:
-12.13%
Intervallo 1D:
$0.645
$0.83
Intervallo di 1 settimana:
$0.4912
$0.83
Portata 52W:
$0.4912
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Nome
Citius Oncology Inc
Settore
Telefono
(908) 967-6677
Indirizzo
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.703 | 62.06M | 0 | -23.64M | -12.89M | -0.3081 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-23 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-11-27 | Iniziato | Maxim Group | Buy |
Citius Oncology Inc Borsa (CTOR) Ultime notizie
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
Citius Oncology reports early adoption metrics for lymphoma drug By Investing.com - Investing.com South Africa
Citius Oncology highlights early LYMPHIR commercial traction, expansion - TipRanks
Citius Oncology advances LYMPHIR launch and global expansion - TipRanks
Citius Oncology reports strong early LYMPHIR launch with broad payer coverage and institutional uptake - TradingView
Citius Oncology reports early adoption metrics for lymphoma drug - Investing.com
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - PR Newswire
Can Citius Oncology Inc keep up with sector leaders2026 Pullbacks & Risk Managed Investment Entry Signals - baoquankhu1.vn
Aug PreEarnings: Should you avoid Sionna Therapeutics Inc stock right now2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Institution Moves: Can Citius Oncology Inc lead its sector in growthTrade Exit Summary & Fast Gain Stock Tips - baoquankhu1.vn
Citius Oncology to Participate in USCLC Annual Workshop 2026, Hi - GuruFocus
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - Nasdaq
Citius Oncology (NASDAQ:CTOR) Trading Down 2.8%Here's What Happened - MarketBeat
Citius Oncology (CTOR) expands Lymphir distribution to Europe through exclusive agreement with Uniphar - MSN
If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - Stock Titan
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius Oncology, Inc.: Fundamental Analysis and Financial Ratings | CTOR | US17331Y1091 - marketscreener.com
Activity Recap: Will Citius Oncology Inc outperform small cap indexes2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com Australia
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data - TipRanks
Citius reports positive Phase 1 topline: 24% ORR, 48% CBR for LYMPHIR + pembrolizumab in gynecologic cancers - TradingView
Citius Oncology Announces Positive Topline Results from Investig - GuruFocus
Citius Oncology, Inc. Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of Lymphir in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - marketscreener.com
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - PR Newswire
Aug EndMonth: Can Citius Oncology Inc lead its sector in growthPortfolio Risk Summary & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Aug Highlights: Does Citius Oncology Inc have strong fundamentalsMarket Risk Analysis & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Finviz
Citius Oncology reports 86% response rate in lymphoma study By Investing.com - Investing.com Canada
Citius Oncology reports 86% response rate in lymphoma study - Investing.com
Citius Oncology, Inc. announces preliminary topline data from its study in high-risk diffuse large B-cell lymphoma patients - Bitget
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan
Citius Oncology reports 86% ORR and favorable safety for LYMPHIR prior to commercial CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat
Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz
New Jersey tax program turns Citius Pharma losses into $3.8M cash - Stock Titan
Citius Oncology Inc Azioni (CTOR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):